by Plus Therapeutics | Dec 18, 2025 | LM
Expert Insights: Dr. Andrew Brenner on the Path Forward In a recent video interview with Sabrina McCrear of AJMC – The American Journal of Managed Care, Andrew Brenner, MD, PhD, provided a deeper look into the significance of the SABCS presentations. Dr. Brenner...
by Plus Therapeutics | Dec 15, 2025 | LM
At the 2025 San Antonio Breast Cancer Symposium (SABCS), Plus Therapeutics and its clinical partners shared important progress in the fight against leptomeningeal metastases (LM) with the presentation of Phase 1 dose escalation results from the ReSPECT-LM clinical...
by Plus Therapeutics | Dec 1, 2025 | LM
Plus Therapeutics is pleased to announce that its abstract has been accepted for a Poster Spotlight with Oral Presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025), taking place December 9–12, 2025, in San Antonio, Texas. This recognition...
by Plus Therapeutics | Nov 24, 2025 | LM
Plus Therapeutics announced that it has successfully completed a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s clinical development plans for REYOBIQ™, its targeted radiotherapeutic for leptomeningeal metastases (LM). The...
by Plus Therapeutics | Nov 10, 2025 | LM
Each November, Lung Cancer Awareness Month serves as a national reminder of the impact lung cancer has on patients, families, and communities. It is also a time to highlight the growing need for better diagnostic and treatment options—especially for patients facing...
by Plus Therapeutics | Nov 6, 2025 | LM
Plus Therapeutics is pleased to announce its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0, taking place on November 9, 2025, in Alexandria, VA. This annual...
Recent Comments